Clik here to view.
Clover Biopharmaceuticals Receives CFDA Approval to Initiate Clinical Trials...
CHENGDU, China Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced it has received Clinical Trial Application (CTA)...
View ArticleClik here to view.
Soliris® (Eculizumab) Receives Marketing Authorization in Japan for the...
NEW HAVEN, Conn. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Soliris® (eculizumab) as a treatment for...
View ArticleClik here to view.
Poxel and Sumitomo Dainippon Pharma Announce Initiation of Phase 3 Program...
LYON, France & OSAKA, Japan POXEL SA (Euronext – POXEL – FR0012432516, hereinafter called “Poxel”), a biopharmaceutical company focused on the development of innovative treatments for metabolic...
View ArticleClik here to view.
Generex Confirms Receipt of $700,000 USD License Fee from Shenzhen BioScien...
MIRAMAR, Fla. Generex Biotechnology Corporation (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) (www.generex.com) today confirmed its receipt of the $700,000 USD up-front license fee (net...
View ArticleClik here to view.
Dr. Xiaoxiang Chen Joins Harbour BioMed as Executive Vice President, Head of...
SHANGHAI, ROTTERDAM, The Netherlands & CAMBRIDGE, Mass. Harbour BioMed announced today the appointment of Dr. Xiaoxiang Chen as Executive Vice President, Head of Clinical Development and...
View ArticleClik here to view.
和铂医药宣布任命陈小祥为和铂医药执行副总裁，临床开发和注册科学负责人
中国上海，荷兰鹿特丹和美国马萨诸塞州 和铂医药（Harbour BioMed）宣布，任命陈小祥医师为执行副总裁，临床开发和注册科学负责人。 本新闻稿包含多媒体。此处查看新闻稿全文： http://www.businesswire.com/news/home/20180103005373/zh-CN/ 陈小祥医师，和铂医药执行副总裁，临床开发和注册科学负责人 (照片：美国商业资讯)...
View ArticleClik here to view.
RenalGuard Systemが心不全患者を対象とする技術評価のヒト初回試験で有望な結果を実証
米マサチューセッツ州ミルフォード （ビジネスワイヤ） — 心血管疾患市場向けの革新的な技術に傾注する医療機器企業のリーナルガード・ソリューションズは本日、体液過剰を伴ううっ血性心不全の患者を対象とする利尿薬療法の体液管理でRenalGuard System®の新規使用を検討するヒト初回実現可能性試験について、良好な結果を報告しました。結果は最近、ドイツのベルリンで開催された年次Devices...
View ArticleClik here to view.
Illumina and KingMed Diagnostics Partner to Develop Next-Generation...
SAN DIEGO Illumina, Inc. (NASDAQ: ILMN) and KingMed Diagnostics (SSE: 603882.SS) today announced an agreement to jointly develop novel oncology and hereditary disease testing applications utilizing...
View ArticleClik here to view.
SanBio Primary Researcher Receives 2017 Smithsonian American Ingenuity Award
MOUNTAIN VIEW, Calif. SanBio, Inc., a leader in regenerative cell therapies for neurological disorders, joins the Smithsonian Institution in recognizing Stanford University’s Dr. Gary Steinberg,...
View ArticleClik here to view.
Takeda and Denali Therapeutics Collaborate to Develop and Commercialize...
OSAKA, Japan & SOUTH SAN FRANCISCO, CA Takeda Pharmaceutical Company Limited (TSE: 4502) and Denali Therapeutics (NASDAQ: DNLI) today announced that they have entered into a strategic option and...
View ArticleClik here to view.
KBP Biosciences Raises $76 Million in Series A Financing and Appoints Brian...
JINAN, China & PHILADELPHIA KBP Biosciences, a private clinical-stage biotechnology company dedicated to the research, development and commercialization of innovative medicines in areas of unmet...
View ArticleClik here to view.
Jiangsu Hengrui Medicine and Arcutis Announce a Development and...
SHANGHAI & MENLO PARK, Calif. Jiangsu Hengrui Medicine Co., Ltd. (SSE: 600276), a fully integrated biopharmaceutical company based in Shanghai, and Arcutis, Inc., a biotechnology company based...
View ArticleClik here to view.
BioProtection Association Expands Global Footprint, Elects New President
BASEL, Switzerland BioProtection Global (BPG), the global association of regional trade organizations representing the biological products industry, announced the incorporation of three new member...
View ArticleClik here to view.
Elastagen to Feature Breakthrough Tissue Repair and Aesthetic Platform at...
SYDNEY Elastagen, a clinical-stage medical technology company with an advanced tissue repair platform based on tropoelastin, today announced that it will showcase the latest clinical developments...
View ArticleClik here to view.
Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement...
SHANGHAI & ROTTERDAM, The Netherlands & CAMBRIDGE, Mass. Harbour BioMed announced today that it has licensed its patented H2L2 transgenic mouse platform for generating fully human...
View ArticleClik here to view.
和铂医药授权百济神州使用其全人源单克隆抗体转基因小鼠平台开发多种全人源单克隆抗体新药
中国上海，荷兰鹿特丹和美国马萨诸塞州剑桥 和铂医药（Harbour BioMed）宣布，已授权百济神州（BeiGene Ltd., NASDAQ: BGNE）, 一家处于商业化阶段的生物医药公司，专注于开发和商业化用于癌症治疗的创新型分子靶向和肿瘤免疫药物, 使用其拥有全球专利技术的H2L2转基因小鼠平台，开发全人源单克隆抗体创新药物。...
View ArticleClik here to view.
和铂医药合作开发全人源抗体片段用于新一代CAR-T细胞免疫治疗
中国上海，荷兰鹿特丹和美国马萨诸塞州剑桥 (美国商业资讯)– 和铂医药今日宣布与艺妙神州医疗科技签署合作协议，开发全人源单克隆抗体片段用于新一代嵌合抗原受体T细胞（CAR-T）细胞免疫治疗。艺妙神州是一家专注于开发CAR-T疗法以治疗血液肿瘤和实体肿瘤的生物科技公司。...
View ArticleClik here to view.
Harbour BioMed Enters Agreement to Develop Fully Human Antibody Fragments for...
SHANGHAI & ROTTERDAM, The Netherlands & CAMBRIDGE, Mass. Harbour BioMed announced today that it has entered into an agreement with ImmunoChina Pharmaceuticals Co. Ltd. to develop fully human...
View ArticleClik here to view.
MabPlex Announces Xinfang Li as Vice President of Process Development
FREMONT, Calif. & YANTAI, SHANDONG, China MabPlex International, a world class CDMO for biologics, announced the appointment of Xinfang Li, Ph.D., to Vice President of Process Development. Dr....
View ArticleClik here to view.
Gynesonics Announces Results from Pivotal IDE Trial for Incision Free...
REDWOOD CITY, Calif. Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced the results from their...
View Article